The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
Bonnie S. Glisson
Research Funding - ImClone Systems
Jennifer Tseng
Research Funding - Lilly
Shanthi Marur
Research Funding - Bristol-Myers Squibb
Dong M Shin
No relevant relationships to disclose
Barbara A. Murphy
Research Funding - ImClone Systems
Ezra E.W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Biodesix
Christopher Y. Thomas
No relevant relationships to disclose
Richard Willey
Employment or Leadership Position - ImClone Systems
Stock Ownership - ImClone Systems
Jan Cosaert
Employment or Leadership Position - ImClone Systems
Honoraria - ImClone Systems
William Nassib William
Research Funding - Astellas Pharma; Lilly; Sanofi
Nusrat Harun
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim